Gumalad, Gabriel .
HRN: 22-34-89 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/25/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/25/2022
01/01/2023
IVT
1.8 G
8 Hrs
Autoimmune Encephalitis
Waiting Final Action
Indication: Empiric Type of Infection: Central Nervous System Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes